Assessment of HCC response to Yttrium-90 radioembolization with gadoxetate disodium MRI: correlation with histopathology

医学 组织病理学 坏死 放射科 核医学 肝细胞癌 介入放射学 凝固性坏死 病理 内科学
作者
Naïk Vietti Violi,Jeffrey Gnerre,Amy Law,Stefanie J. Hectors,Octavia Bane,John T. Doucette,Ghadi Abboud,Edward Kim,Myron Schwartz,Maria Isabel Fiel,Bachir Taouli
出处
期刊:European Radiology [Springer Science+Business Media]
卷期号:32 (9): 6493-6503 被引量:15
标识
DOI:10.1007/s00330-022-08732-4
摘要

Transarterial 90Y radioembolization (TARE) is increasingly being used for hepatocellular carcinoma (HCC) treatment. However, tumor response assessment after TARE may be challenging. We aimed to assess the diagnostic performance of gadoxetate disodium MRI for predicting complete pathologic necrosis (CPN) of HCC treated with TARE, using histopathology as the reference standard. This retrospective study included 48 patients (M/F: 36/12, mean age: 62 years) with HCC treated by TARE followed by surgery with gadoxetate disodium MRI within 90 days of surgery. Two radiologists evaluated tumor response using RECIST1.1, mRECIST, EASL, and LI-RADS-TR criteria and evaluated the percentage of necrosis on subtraction during late arterial, portal venous, and hepatobiliary phases (AP/PVP/HBP). Statistical analysis included inter-reader agreement, correlation between radiologic and pathologic percentage of necrosis, and prediction of CPN using logistic regression and ROC analyses. Histopathology demonstrated 71 HCCs (2.8 ± 1.7 cm, range: 0.5–7.5 cm) including 42 with CPN, 22 with partial necrosis, and 7 without necrosis. EASL and percentage of tumor necrosis on subtraction at the AP/PVP were independent predictors of CPN (p = 0.02–0.03). Percentage of necrosis, mRECIST, EASL, and LI-RADS-TR had fair to good performance for diagnosing CPN (AUCs: 0.78 – 0.83), with a significant difference between subtraction and LI-RADS-TR for reader 2, and in specificity between subtraction and other criteria for both readers (p-range: 0.01–0.04). Radiologic percentage of necrosis was significantly correlated to histopathologic degree of tumor necrosis (r = 0.66 – 0.8, p < 0.001). Percentage of tumor necrosis on subtraction and EASL criteria were significant independent predictors of CPN in HCC treated with TARE. Image subtraction should be considered for assessing HCC response to TARE when using MRI. • Percentage of tumor necrosis on image subtraction and EASL criteria are significant independent predictors of complete pathologic necrosis in hepatocellular carcinoma treated with 90 Y radioembolization. • Subtraction, mRECIST, EASL, and LI-RADS-TR have fair to good performance for diagnosing complete pathologic necrosis in hepatocellular carcinoma treated with 90 Y radioembolization.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
哭哭完成签到 ,获得积分10
刚刚
科研通AI6.4的应助被俏皮幻悲采纳,获得10
1秒前
1秒前
1秒前
乐乐的应助被路人采纳,获得10
2秒前
科研白发布了新的文献求助10
2秒前
科研白发布了新的文献求助10
2秒前
科研白发布了新的文献求助10
3秒前
蒸馒头争气完成签到,获得积分10
3秒前
科研白发布了新的文献求助10
3秒前
3秒前
科研白发布了新的文献求助10
3秒前
侯锐淇发布了新的文献求助10
3秒前
3秒前
4秒前
4秒前
SLKG发布了新的文献求助10
5秒前
慕青的应助被开心的紫烟采纳,获得10
5秒前
6秒前
rs10发布了新的文献求助10
7秒前
7秒前
Reyna完成签到,获得积分10
7秒前
凡人修仙完成签到,获得积分10
7秒前
eric888完成签到,获得积分0
8秒前
折古发布了新的文献求助10
9秒前
溯光完成签到,获得积分10
9秒前
9秒前
科研白发布了新的文献求助10
9秒前
NatureWang发布了新的文献求助10
9秒前
思源的应助被武灿灿采纳,获得10
10秒前
Xpearl完成签到,获得积分10
10秒前
10秒前
无情愫的应助被key采纳,获得10
10秒前
10秒前
000完成签到 ,获得积分10
10秒前
学霸业的应助被无私的遥采纳,获得10
11秒前
13秒前
英姑的应助被zzzz采纳,获得30
13秒前
Csufters.发布了新的文献求助10
13秒前
DW的应助被hsadu采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Energie-Contracting 1500
Mathematical models in hydrology 1000
Klimaschutzrecht durch den Energiesektor im Mehrebenensystem – Ein Rechtsvergleich 1000
Oncology Clinical Trials: Successful Design, Conduct, and Analysis, Second Edition 800
Erzählte Gnade 500
Butadiene hydroxytelechelic oligomers PBHT 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8082925
求助须知:如何正确求助?哪些是违规求助? 9498174
关于积分的说明 21405279
捐赠科研通 7651066
什么是DOI,文献DOI怎么找? 3402081
关于科研通互助平台的介绍 2531108
邀请新用户注册赠送积分活动 2440677